STRO:NASDAQSutro Biopharma, Inc. Analysis
Data as of 2026-09-14 - not real-time
$16.91
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Sutro Biopharma, Inc. trades at $16.91, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Over a rolling month the price has lost 30.0%. Relative strength is 25.7 — oversold — and the MACD signal is bearish. Price has been bracketed by support at $16.48 and resistance at $23.45.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 179.3% above where the shares trade now. Revenue is contracting at 84.6%.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 67.9%, a beta of 1.20 and a maximum drawdown of 58.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 179.3% above where the shares trade now. Revenue is contracting at 84.6%.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 67.9%, a beta of 1.20 and a maximum drawdown of 58.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top Market Events
- Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable...Sutro Biopharma, Inc. STRO shares are trading lower on Wednesday as the company faces challenges following its recent...Yahoo Finance1monSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- RSI at 25.7 signals oversold conditions
- Trading below the 200-day average of 22.48
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- RSI at 25.7 signals oversold conditions
- Trading below the 200-day average of 22.48
- Analyst targets imply +179.3% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +179.3% versus the current price
- Revenue contracting at -84.6%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth-84.60%
P/E Ratio-2.7
ROA-36.08%
P/B Ratio-2.7
Op. Cash Flow$-145172992
Free Cash Flow$-100756000
Industry P/E30.0
Technical Analysis
TrendNeutral
RSI25.7
Support$16.48
Resistance$23.45
MA 20$20.24
MA 50$23.22
MA 200$22.48
MACDBearish
VolumeStable
Fear & Greed Index90.89
Valuation
Target Price$47.23
Upside/Downside179.31%
GradeFair
TypeBlend
Risk Assessment
Beta1.20
Volatility67.88%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.